Australia’s Therapeutic Goods Administration (TGA) has issued a new safety alert for GLP-1 drugs—including Ozempic, Wegovy, Saxenda, Trulicity, and Mounjaro—highlighting potential risks of new or worsening depression, suicidal thoughts, and unusual mood changes.

The TGA acknowledged a complex relationship between medication effects, mental health, and rapid weight loss. The agency has received more than 70 reports of suicidal ideation and additional reports of suicide attempts or deaths among users.

MISSD believes all patients deserve truthful, transparent information about the risks of medication-induced symptoms that can lead to self-harm or suicide. Early recognition and accurate diagnosis of medication-induced akathisia and other adverse effects can save lives.

Read the full article at https://www.qoo10.co.id/en/international/50876/watchdog-updates-safety-warnings-on-ozempic-like-drugs-over-suicidal-thoughts-risk/.

Whether you support our mission with a tax-deductible gift, or by sharing our free resources with colleagues, family and friends, MISSD is grateful to have so many thoughtful people dedicated to saving lives and reducing avoidable harms. See our Constant Contact message and highlights here https://conta.cc/42p3aDG

New VA legislation encourages the use of AI tools to identify veterans at risk of suicide. For these systems to truly protect veterans–and everyone–MISSD believes they must include information about akathisia and medication-induced suicidality. Avoidable deaths can be prevented when the causes, risks and symptoms of akathisia are better understood, recognized and treated.

Read the full article at https://www.military.com/daily-news/investigations-and-features/2025/11/20/lawmakers-va-use-ai-help-prevent-veteran-suicide.html?ESRC=eb_251201.nl.

At Michigan’s State Capitol last week, veterans, clinicians, and caregivers united to advance safer mental health care. Together, we’re raising awareness of medication-induced harms including akathisia and suicide — because every life matters. https://www.youtube.com/watch?v=V38eplKFnTU

Today MISSD honors those who have served as we continue our mission to prevent medication-induced harm and avoidable deaths. In our latest Akathisia Stories episode, veteran Derek Blumke from the Grunt Style Foundation, and MISSD founder, Wendy Dolin, share insights about the need for akathisia training, informed consent, and the current state of mental health care for veterans. Listening to those most affected is a critical step to creating positive change.

🎧 Stream now: https://www.youtube.com/watch?v=VfiEKD2ePJ0&t=292s.

Today we honor veterans in action at the Michigan State Capitol with a collaborative event focused on reducing preventable medication harm. The training includes MISSD’s latest akathisia course, a screening of the documentary Medicating Normal, and a panel of experts, clinicians, and veterans whose voices call for safer care and accurate information about real drug risks.

Read more at https://www.einpresswire.com/article/863954945/veterans-month-medication-and-suicide-prevention-event-hosted-at-michigan-state-capitol-november-5.

Today there’s a new call for clinical trial participants regarding psychiatric meds and pregnancy. MISSD supports improved data collection and transparent communication to improve patient safety.

The trial may uncover important finidings given that research shows that when taken during pregnancy, SSRIS can be associated with an increased risk of congenital heart defects and that up to 30% of exposed newborns may experience withdrawal symptoms after birth. Accurate info can help parents, clinicians, and researchers make better-informed decisions.

For more info, see https://www.medpagetoday.com/clinical-trial-finder/study/nct01246765?category=psychiatry&topic=adhd&xid=nl_mpt_clinicaltrials_psychiatry2025-10-27&mh=b36786d8242d266f4bb652c0dc8afd66&zdee=gAAAAABm4u6co5yqhud2n1bxWGd7sMMIzGODjyi5yiJbiU776UmtHFCJ1kENUJt34LAE9XQZhrz9RcsNavUdU6W-qeehZ2pcj8fzrTXl0-WR5k-uKQbKQrg%3D

Healthcare professionals, consumers, veterans and caregivers in Michigan are invited to join us for a vital training day. Earn CEUs, take our new akathisia course, hear from experts by experience, and help save lives. Register at https://www.eventbrite.com/e/veteran-harms-reduction-training-tickets-1765772255349.

A new study comparing depression pill side effects missed a key opportunity to address a misunderstood issue: SSRI withdrawal symptoms are not relapse.

When people stop or switch SSRIs and experience agitation, anxiety, electronic “brain zap” sensations, and/or severe restlessness, these symptoms can signal withdrawal akathisia or SSRI withdrawal syndrome — not a return of depression.

Mislabeling withdrawal as relapse can lead to dangerous prescribing and unnecessary suffering.

Prescribers and consumers deserve clear information about known drug risks. Read the full article at https://pharmaceutical-journal.com/article/news/researchers-call-for-update-to-antidepressant-guidelines.

As countries mark World Mental Health Day, MISSD calls on drug regulators to strengthen suicide warnings and clearly communicate that the medication can cause akathisia and other severe side effects.

“People in every country deserve accurate information about medication risks,” said Wendy Dolin, MISSD founder. “Yet warnings are often missing or inconsistent across borders. Greater awareness and transparency can save lives.”

France just became the first nation to add a clear finasteride suicide warning—will the U.S. follow? Read the release at: https://www.einpresswire.com/article/856770655/missd-calls-for-global-action-on-medication-induced-suicide-risks.